MGB Biopharma

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise.

Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections.

MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

Company type
Dr Miroslav Ravic
Mr Raymond Spencer

MiNA Therapeutics

MiNA Therapeutics is a virtual biotechnology company pioneering the activation of gene expression with short activating RNA (saRNA).

Harnessing a proprietary algorithm, MiNA is developing a revolutionary class of therapeutics that activate key genes in major disease pathways. MiNA's ability to selectively activate master regulatory genes represents a new frontier in precision medicine.

MTL-501 is a saRNA liver cancer therapeutic that activates the CEBPA gene. Intravenous injection of MTL-501 in a liver cancer rat model reduced tumour burden by 80% whilst increasing significantly serum albumin. In vitro work has indicated the dramatic potential of CEBPA saRNA as a universal anti-cancer therapeutic in non-small cell lung, prostate, pancreas, leukaemia, lymphoma and glioblastoma. MTL-301 is a Type 1 diabetes therapeutic. In vitro work demonstrated glucose responsive insulin secretion by both CD34+ adult stem cells and HepG2 cells.
Website:
www.minatx.com
Company type
Mr Robert Habib
CEO